MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.

Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 5 a.m. PT on Tuesday, Nov. 26, 2024, to ...

Amgen (NASDAQ:AMGN) today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide ...

It will be interesting to see what dosing strategy is pursued in the Phase III study. Finally, MariTide was also studied in patients with type 2 diabetes. Robust weight loss was again observed ...

Despite some market volatility due to uncertainty over data differentiation with competitors, the continued development of MariTide into Phase 3 trials for obesity and related conditions underpins ...

Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart cafraglutide, ...

Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in ...

According to phase 2 study, MariTide achieved significant weight loss in individuals with obesity or overweight, with up to ...

Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133) and progress on its development program. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief ...

Nov. 26, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide (maridebart cafraglutide, formerly AMG 133 ...